All In Biotech

Drug Trial Radar · NCT02031640

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

Last checked: Nov 19, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,113 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,113

Actual

Start

Dec 2013

Primary completion

Nov 2014

Study completion Dec 2014

Sponsor

Sponsor type
Industry
First posted
Jan 9, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, placebo-controlled, double-blind,double-dummy, parallel-group, 12-week study in male and female patients, 12 years of age and older, with persistent asthma.

Conditions

  • Asthma

Interventions

  • Beclomethasone dipropionateDrug

  • PlaceboDrug

  • Albuterol/salbutamolDrug

    Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Standardized Baseline-adjusted Trough Morning Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk) )Time frame: Day 1 (baseline), Weeks 2, 4, 8, 12

Locations

131 sites in 4 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 10851

    Costa Mesa, California

  • Teva Investigational Site 10849

    Huntington Beach, California

  • Teva Investigational Site 10872

    Huntington Beach, California

  • Teva Investigational Site 10833

    Long Beach, California

  • Teva Investigational Site 10861

    Los Angeles, California

  • Teva Investigational Site 10798

    Mission Viejo, California

  • Teva Investigational Site 10806

    Orange, California

  • Teva Investigational Site 10828

    Orange, California

  • Teva Investigational Site 10860

    Paramount, California

  • Teva Investigational Site 10813

    Rancho Mirage, California

  • Teva Investigational Site 10843

    Riverside, California

  • Teva Investigational Site 10857

    Rolling Hills Estates, California

  • Teva Investigational Site 10847

    San Diego, California

  • Teva Investigational Site 10871

    San Diego, California

  • Teva Investigational Site 10876

    San Jose, California

  • Teva Investigational Site 12270

    Walnut Creek, California

  • Teva Investigational Site 12266

    Centennial, Colorado

  • Teva Investigational Site 10838

    Colorado Springs, Colorado

  • Teva Investigational Site 10844

    Denver, Colorado

  • Teva Investigational Site 10799

    Wheat Ridge, Colorado

  • Teva Investigational Site 10826

    Aventura, Florida

  • Teva Investigational Site 10877

    Clearwater, Florida

  • Teva Investigational Site 10816

    Edgewater, Florida

  • Teva Investigational Site 12268

    Melbourne, Florida

  • Teva Investigational Site 10807

    Miami, Florida

  • Teva Investigational Site 10840

    Miami, Florida

  • Teva Investigational Site 12269

    Miami, Florida

  • Teva Investigational Site 10875

    Sarasota, Florida

  • Teva Investigational Site 10855

    Tallahassee, Florida

  • Teva Investigational Site 10864

    Tampa, Florida

  • Teva Investigational Site 10858

    Albany, Georgia

  • Teva Investigational Site 10862

    Lawrenceville, Georgia

  • Teva Investigational Site 10848

    Savannah, Georgia

  • Teva Investigational Site 10829

    River Forest, Illinois

  • Teva Investigational Site 10809

    Indianapolis, Indiana

  • Teva Investigational Site 10795

    Iowa City, Iowa

  • Teva Investigational Site 10870

    Owensboro, Kentucky

  • Teva Investigational Site 10832

    Baltimore, Maryland

  • Teva Investigational Site 10850

    Bethesda, Maryland

  • Teva Investigational Site 10873

    Wheaton, Maryland

Showing 40 of 131 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.